Fennec Pharmaceuticals Inc (FENC) - Total Liabilities
Based on the latest financial reports, Fennec Pharmaceuticals Inc (FENC) has total liabilities worth $34.15 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Fennec Pharmaceuticals Inc - Total Liabilities Trend (1999–2025)
This chart illustrates how Fennec Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See Fennec Pharmaceuticals Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Fennec Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Fennec Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Capol International & Associates Co Ltd
SHE:002949
|
China | CN¥1.34 Billion |
|
Precious Shipping Public Company Limited
BK:PSL-R
|
Thailand | ฿9.21 Billion |
|
Medios AG
XETRA:ILM1
|
Germany | €398.53 Million |
|
Reconnaissance Energy Africa Ltd
V:RECO
|
Canada | CA$4.67 Million |
|
E1 Corporation
KO:017940
|
Korea | ₩13.31 Trillion |
|
Jiangsu Gaoke Petrochemical Co
SHE:002778
|
China | CN¥361.51 Million |
|
United Malacca Bhd
KLSE:2593
|
Malaysia | RM282.23 Million |
|
Pro Real Estate Investment Trust
TO:PRV-UN
|
Canada | CA$578.57 Million |
Liability Composition Analysis (1999–2025)
This chart breaks down Fennec Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see FENC stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.91 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fennec Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fennec Pharmaceuticals Inc (1999–2025)
The table below shows the annual total liabilities of Fennec Pharmaceuticals Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $35.02 Million | -31.10% |
| 2024-12-31 | $50.82 Million | +32.04% |
| 2023-12-31 | $38.49 Million | +30.43% |
| 2022-12-31 | $29.51 Million | +344.26% |
| 2021-12-31 | $6.64 Million | +183.00% |
| 2020-12-31 | $2.35 Million | +3.35% |
| 2019-12-31 | $2.27 Million | +38.73% |
| 2018-12-31 | $1.64 Million | -0.43% |
| 2017-12-31 | $1.64 Million | +308.96% |
| 2016-12-31 | $402.00K | -14.65% |
| 2015-12-31 | $471.00K | -73.22% |
| 2014-12-31 | $1.76 Million | -45.15% |
| 2013-12-31 | $3.21 Million | -56.20% |
| 2012-12-31 | $7.32 Million | +33.83% |
| 2011-12-31 | $5.47 Million | -49.89% |
| 2010-12-31 | $10.92 Million | +2456.67% |
| 2009-12-31 | $427.00K | -85.80% |
| 2008-12-31 | $3.01 Million | -1.76% |
| 2007-12-31 | $3.06 Million | -65.99% |
| 2006-12-31 | $9.00 Million | +7.28% |
| 2005-12-31 | $8.39 Million | -3.94% |
| 2003-12-31 | $8.73 Million | -15.63% |
| 2002-12-31 | $10.35 Million | +1306.04% |
| 2001-12-31 | $736.04K | +15.84% |
| 2000-12-31 | $635.41K | +6.53% |
| 1999-12-31 | $596.46K | -- |
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has co… Read more